MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Net Income 2011-2026 | NVTA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -99.8 M | -205 M | -602 M | -242 M | -129 M | -123 M | -100 M | -89.8 M | -47.5 M | -24.8 M | -8.6 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.6 M | -602 M | -152 M |
Quarterly Net Income Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -942 M | -207 M | -192 M | - | -301 M | -2.52 B | -182 M | -205 M | -198 M | 134 M | -109 M | -234 M | -103 M | -166 M | -98.5 M | -76.9 M | -78.7 M | -48.7 M | -37.7 M | -29.8 M | -31.7 M | -31.7 M | -36.1 M | -40.5 M | -27.4 M | -123 M | -123 M | -24.8 M | -100 M | -100 M | -100 M | -24.4 M | -22.5 M | -24.3 M | -18.6 M | -15.3 M | -12.6 M | -10.5 M | -9.03 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | -2.52 B | -170 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
-12.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.21 B | $ 116.52 | 2.33 % | $ 35.4 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.19 | 1.28 % | $ 6.48 M | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.91 | -4.44 % | $ 8.45 M | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 17.7 | 0.17 % | $ 943 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 15.99 | -0.62 % | $ 172 M |  China |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 24.93 | 0.4 % | $ 692 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 175.31 | 3.36 % | $ 8.69 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Danaher Corporation
DHR
|
3.61 B | $ 196.21 | 2.72 % | $ 140 B | USA |
 |
DexCom
DXCM
|
836 M | $ 65.46 | 3.72 % | $ 25.5 B | USA |
 |
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 15.87 | -0.25 % | $ 480 M | USA |
 |
Quotient Limited
QTNT
|
-111 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Guardant Health
GH
|
-416 M | $ 92.47 | -0.89 % | $ 11.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.68 | -0.37 % | $ 87 K | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 107.91 | 0.7 % | $ 8.9 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | Israel |
 |
Illumina
ILMN
|
-1.22 B | $ 128.62 | 1.72 % | $ 20.5 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 116.36 | 0.69 % | $ 5.44 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 275.47 | 2.34 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 80.04 | 2.51 % | $ 5.4 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 198.5 | 0.87 % | $ 22 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 320.7 | 3.99 % | $ 27.2 B | Schweiz |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.72 | -0.32 % | $ 437 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 5.04 | -5.62 % | $ 3.97 M | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 10.29 | 3.06 % | $ 2.23 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.53 | 2.88 % | $ 392 M | USA |
 |
Natera
NTRA
|
-548 M | $ 211.52 | 1.08 % | $ 20.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.45 | 0.35 % | $ 435 M | USA |